318 filings
Page 5 of 16
424B5
y3gatkqm9 clq3wdbuc
15 Mar 17
Prospectus supplement for primary offering
12:00am
424B5
q4g95ma
13 Mar 17
Prospectus supplement for primary offering
12:00am
8-K
mwkyo1vqgxulio
27 Feb 17
Anthera Pharmaceuticals Provides Business Update
12:00am
8-K
iuhocjyt9x4
16 Feb 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
vukp7gda6 wo486
6 Jan 17
Regulation FD Disclosure
12:00am
8-K
4nd3gff79avkb8
27 Dec 16
Other Events
12:00am
8-K
oltq02h9u6rv3rr
6 Dec 16
Anthera Announces Leadership Transition in Preparation of Commercialization of Sollpura and Future Development of blisibimod for IgA Nephropathy
12:00am
8-K
sza7js2rxuur5
1 Dec 16
Regulation FD Disclosure
12:00am
8-K
ctp0t6j0myjvadfb2p
10 Nov 16
Anthera Announces that the Blisibimod CHABLIS-SC1 Phase 3 Study
12:00am
8-K
cd6du9
4 Nov 16
Anthera Pharmaceuticals Provides Business Update and Reports 2016 Third Quarter Financial Results
12:00am
S-8
rz4ftoln97e1ntm8 2z
4 Oct 16
Registration of securities for employees
12:00am
8-K
ijt231g pe3
15 Sep 16
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
0m8arbtpem2ng398b7ea
12 Sep 16
Anthera Pharmaceuticals Announces Initial $17.0 Million Closing of a Potential $45.33 Million
12:00am
424B5
m7if6pozluxj51xdsgf
8 Sep 16
Prospectus supplement for primary offering
12:00am
8-K
brk10z1b
16 Aug 16
Anthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as Chief Medical Officer
12:00am
8-K
0q4aike 2dqqta
9 Aug 16
Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results
12:00am